Compare Regeneron Pharmaceuticals Inc (REGN) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Walmart Stores Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Walmart Stores Inc trades at $109.49 (market cap $878.49B). The key difference: Walmart Stores Inc is far larger — about 12.4× Regeneron Pharmaceuticals Inc's market cap, and Walmart Stores Inc pays the higher dividend (0.9%). Which is the better fit depends on your goals.
| REGN | WMT | |
|---|---|---|
Market Cap | $70.79B | $878.49B |
Sector | Health | Consumer Staples |
52-Week High | $812.27 | $134.20 |
52-Week Low | $545.46 | $95.68 |
Enterprise Value | $64.74B | $941.94B |
Dividend Yield | 0.56% | 0.9% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Walmart (WMT) trades at $112.20, down 1.79% amid bearish technical signals despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS expected at $0.74. Revenue growth remains robust at $681B for 2025, with net income margin improving to 3.13%. Technical indicators show bearish momentum with support at $109 and resistance at $114.
Walmart presents a compelling long-term investment with 73% analyst buy ratings and $142.33 consensus price target representing 27% upside. Risks include competitive pressure from Amazon, margin compression concerns, and economic sensitivity. The company's strong cash flow generation and dividend program provide shareholder value stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
